Scope
Focused selection from the ADA 2026 Standards covering adult diagnosis and prevention, self-management and nutrition, older adults, pregnancy, and hospital care. Targets and treatment choices depend on population and setting; these selected recommendations do not constitute the complete Standards or a comprehensive glucose-lowering drug algorithm.
Written by House with AI assistance · AI-assisted source check 29 October 2026.
This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.
Diagnosis and screening
- In nonpregnant individuals, diagnostic thresholds are A1C ≥6.5%, fasting plasma glucose ≥126 mg/dL after at least eight hours without calories, or two-hour glucose ≥200 mg/dL during a 75-g OGTT. Use an NGSP-certified, DCCT-standardised laboratory A1C method. [2]
- Random plasma glucose ≥200 mg/dL diagnoses diabetes when classic hyperglycaemic symptoms or hyperglycaemic crisis are present. Without unequivocal hyperglycaemia, require two abnormal results: different tests taken together or the same test at separate time points. [2]
- When A1C may not reflect glycaemia reliably—for example with altered red-cell turnover, pregnancy or some haemoglobin variants—use plasma glucose criteria. Investigate substantial A1C–glucose discordance for assay problems or interference. Both recommendations carry grade B. [2]
- Consider testing asymptomatic adults of any age with overweight or obesity plus another risk factor (B); otherwise begin at 35 years (B). If screening is normal, repeat at least every three years, sooner for symptoms or changed risk (C). [2]
Prevention and continuing support
- Refer adults with overweight or obesity at high risk of type 2 diabetes to a prevention programme targeting sustained loss of at least 5–7% of initial weight and ≥150 minutes weekly of moderate activity with healthy reduced-calorie eating (A). [3]
- Consider metformin for high-risk adult diabetes prevention, especially ages 25–59, BMI ≥35 kg/m², higher fasting glucose or A1C, or previous gestational diabetes (A). Consider periodic vitamin B12 assessment during long-term metformin, particularly with anaemia or neuropathy (B). [3]
- Refer people with prediabetes or diabetes for individualised medical nutrition therapy from an experienced dietitian (A). Individualise meal plans around nutritional quality, calories and metabolic goals (B), rather than imposing one universal diet. [5]
- Advise developmentally and culturally appropriate diabetes self-management education and support for everyone with diabetes (A). Provide it at diagnosis, annually or when goals are unmet, with complicating factors, and during transitions in life or care (E). [5]
Individualising care in older adults
- For older adults with diabetes, few stable comorbidities, and intact cognition and function, an A1C goal such as <7.0–7.5% is appropriate; select the goal with the individual rather than applying it to frail populations (C). [6]
- For older adults with significant cognitive or functional limitations, frailty, severe comorbidity or an unfavourable treatment risk–benefit balance, prioritise hypoglycaemia avoidance and individualise less stringent goals, such as A1C <8.0% (C). [6]
- For older adults with very complex or poor health, focus on preventing hypoglycaemia and symptomatic hyperglycaemia; stringent glycaemic goals offer little benefit (C). [6]
- In older adults at high hypoglycaemia risk, deintensify insulin, sulfonylureas or meglitinides, or use lower-risk alternatives within individual goals (B). Simplify complex regimens, particularly insulin (B); reduce treatment when burdens or harms exceed benefits (E). [6]
Pregnancy and postpartum care
- Discuss pregnancy planning from puberty in people with diabetes and childbearing potential. Use effective contraception until treatment and A1C are optimised; aim before conception for A1C <6.5% if achievable without excessive hypoglycaemia (A). [8]
- In diabetes during pregnancy, monitor fasting, premeal and postmeal glucose. Targets are fasting <95 mg/dL and either one-hour postmeal <140 mg/dL or two-hour postmeal <120 mg/dL (B). [8]
- During pregnancy, aim ideally for A1C <6% if this avoids significant hypoglycaemia; relax to <7% when needed to prevent hypoglycaemia (B). Do not use estimated A1C or glucose management indicator as pregnancy A1C estimates (C). [8]
- Lifestyle change is essential in gestational diabetes; add insulin when needed to reach glucose goals (A). Insulin is required for type 1 diabetes in pregnancy (A) and is the preferred agent for gestational diabetes (A) and type 2 diabetes in pregnancy (B). [8]
- After gestational diabetes, screen at 4–12 weeks postpartum with a 75-g OGTT using nonpregnancy diagnostic criteria (B), then screen lifelong every 1–3 years for diabetes or prediabetes (B). Reassess insulin immediately after delivery because requirements can fall sharply (C). [8]
Hospital assessment and glycaemic treatment
- At hospital admission, obtain A1C in people with diabetes or random glucose >140 mg/dL if no result is available from the previous three months (B). [9]
- For most hospitalised adults, persistent glucose ≥180 mg/dL on two occasions within 24 hours prompts treatment initiation or intensification: insulin in critical illness (A), and insulin and/or other glucose-lowering therapy outside intensive care (B). [9]
- For most critically ill adults receiving treatment, target glucose 140–180 mg/dL (A); tighter individual goals require avoiding significant hypoglycaemia (B). Outside critical care, target 100–180 mg/dL if achievable without significant hypoglycaemia (B). [9]
- Use continuous intravenous insulin for critical illness (A). Outside critical care, prefer basal or basal-plus-correction insulin with poor or no intake, and basal–prandial–correction insulin with adequate intake (A). Correction-only insulin without basal insulin is discouraged for most inpatients (A). [9]
- Continue a personal CGM in hospital when clinically appropriate and resources, training and institutional protocols support it; confirm with point-of-care glucose for insulin decisions and hypoglycaemia assessment (B). [9]
- Use an institutional hypoglycaemia protocol and an individual prevention and treatment plan. Document and track episodes; review and change treatment as necessary after any glucose <70 mg/dL to prevent recurrence (C). [9]
- Provide an individualised discharge plan (B), accounting for the destination facility’s diabetes-management capability when discharge is not home (E). People affected by, or at high risk of, DKA or HHS need education on recognition, prevention and management before discharge (B). [9]
Limitations and use
- This is a selected clinical summary, not the complete ADA Standards. It does not cover the comprehensive drug-selection, cardiovascular, kidney, retinopathy, neuropathy, foot-care or technology algorithms, nor complete paediatric or hyperglycaemic-crisis protocols.
- Pregnancy, older-adult and inpatient targets are distinct; they should not be transferred to other populations. Medication availability, costs, monitoring and local Indian practice require individual assessment.
- Letters A, B, C and E are the ADA evidence grades accompanying the selected recommendations; E denotes expert consensus or clinical experience.
- This House summary is based on the linked focused or condensed recommendation sources; it does not represent the complete original publication.
This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.
Summary sources
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 1
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 2
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 3
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 4
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 5
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 6
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 7
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 8
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 9
Selected recommendation material consulted
- Standards of Care in Diabetes — 2026 — reviewed source bundle part 10
Selected recommendation material consulted
Publication details
- Issuing organisation
- American Diabetes Association
- Resource type
- Clinical guideline · House clinical summary
Earlier House summaries: type 2 diabetes in adults ada · inpatient hyperglycaemia management ada
The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.